Ascendis Pharma A/S

ASND · Nasdaq · Denmark

Share price · ASND

$270.33+21.48 (+8.63%) 3M

close as of 2026-11-18 · 24h delayed · vol 568K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ASND's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 15 Sep 2026-9.5%
  2. 31 Aug 2026+6.1%
  3. 25 Jun 2026+9.9%

    Nothing announced by ASND that day or the session before.

  4. 29 May 2026-5.6%

    Nothing announced by ASND that day or the session before.

  5. 22 Apr 2026-3.8%

Share of unusual movement by asset

For each asset, the share of ASND's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
palopegteriparatide (Yorvipath)
events and moves
3shown from 8 days
lonapegsomatropin (Skytrofa)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—45%
Sessions with no dated event—55%

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Growth hormone receptorProtein / enzyme therapeutic
Growth Hormone Deficiency
Approved
PTH1 receptor (PTH replacement)Peptide
Hypoparathyroidism

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
palopegteriparatide · YorvipathPhase 3Hypoparathyroidism
Est. primary completion 2027-08 · NCT07706764 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
lonapegsomatropin · SkytrofaPhase 3Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Est. primary completion 2028-02 · NCT07221851 · CT.gov ↗
What to watch
September 2028 (1)
lonapegsomatropin · SkytrofaPhase 3Achondroplasia
Est. primary completion 2028-09 · NCT07924059 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (13)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$250M$78M$633M$71M$2.5M operating cash flowreport ↗

Ascendis Pharma Oncology Division A/S reported revenue of $249.65M, up 293.1% YoY, R&D spend of $78.16M, down 3.2% YoY, cash and equivalents of $632.51M, and a net loss of $71.27M for Q3 2025.

Figures only: this period's report disclosed no narrative text

View 12 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2$179M$82M$579M$44M-$8.3M operating cash flowreport ↗
2025-Q1$106M$91M$561M$100M-$15M operating cash flowreport ↗
2024-Q3$64M$81M$699M$109M-$62M operating cash flowreport ↗
2024-Q2$39M$90M$277M$118M-$66M operating cash flowreport ↗
2024-Q1$104M$77M$346M$142M-$110M operating cash flowreport ↗
2023-Q3$52M$121M$466M$177M-$136M operating cash flowreport ↗
2023-Q2$52M$114M$428M$132M-$167M operating cash flowreport ↗
2023-Q1$36M$114M$547M$119M-$158M operating cash flowreport ↗
2022-Q3$15M$98M$598M$170M-$100M operating cash flowreport ↗
2022-Q2$6.6M$96M$702M$87M-$133M operating cash flowreport ↗
2022-Q1$7.7M$93M$843M$141M-$147M operating cash flowreport ↗
2021-Q3$1.3M$69M$804M$95M-$115M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$816M$344M$724M$65M$61M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$394M$332M$582M$102M-$331M operating cash flowreport ↗
2023-FY$289M$447M$434M$130M-$506M operating cash flowreport ↗
2022-FY$54M$400M$474M$154M-$522M operating cash flowreport ↗
2021-FY$9.2M$350M$505M$113M-$494M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 9 purchases ($777K), 4 sales ($10.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG · EVP & Chief Admin OfficerOption exercise20,000$37.18$744KForm 4
2026-11-17PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG · EVP & Chief Admin OfficerOpen-market sale20,000$263.89$5.3MForm 4
2026-11-17PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG · EVP & Chief Admin OfficerOption exercise (derivative)20,000——Form 4
2026-09-08Bodenhoff Mads · SVP & PAOOption exercise3,000$110.00$330KForm 4
2026-09-08Bodenhoff Mads · SVP & PAOOpen-market sale3,000$270.19$811KForm 4
2026-09-08Bodenhoff Mads · SVP & PAOOption exercise (derivative)3,000——Form 4
2026-09-02HOLTUG LARS · directorOpen-market sale236$264.13$62KForm 4
2026-08-14BIENAIME JEAN JACQUES · directorOpen-market purchase1,100$245.85$270KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 7 reporting institutions held 7.9M shares ($34.4M).

#InstitutionSharesValue
1Driehaus Capital Management LLC127,562$29.2M
2Evolutionary Tree Capital Management, LLC9,070$2.1M
3T. Rowe Price Investment Management, Inc.6,162,042$1.4M
4PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO5,784$1.3M
5PRICE T ROWE ASSOCIATES INC /MD/1,530,345$350K
6Q Global Advisors, LLC100,000$23K
7SBI Securities Co., Ltd.3$686